Skip to content
Screener

Indivior Pharmaceuticals, Inc. INDV Business Segments — Operating Income (Loss)

Similar metrics at other companies

Target logo
TGTReportable Segment — Operating Income (Loss)
$1.14B-22.9%
Ross Stores logo
ROSTReportable Segment — Operating Income (Loss)
$804.03M+32.6%
Williams-Sonoma logo
WSMReportable Segment — Operating Income (Loss)
$291.69M+0.3%
Samsara logo
IOTReportable Segment — Operating Income (Loss)
$7.2M+122%
ALX
ALXReportable Segment — Operating Income (Loss)
$24.43M-16.8%
The Buckle logo
BKEReportable Segment — Operating Income (Loss)
$59.45M+36.5%

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.57B+66.3%
Enterprise value$4.9B+88.3%
P/E18.2×-7.2×
P/S3.5×+1.2×

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%

Returns & leverage

See full
Return on equity-117%
Debt / equity-3.5×
Current ratio0.9×0.0×

Where this comes from

Reported directly by Indivior Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:02 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028850
Line itemThree Months Ended March 31, 20262025
Selling, general and administrative124133
Research and development1622
Total operating expenses139156
Operating income13766
Other (income) and expenses:
Interest (income)(3)(4)
Interest expense712
Loss on debt extinguishment18

Item 1. Unaudited Condensed Financial Statements.

FAQ

What is Indivior Pharmaceuticals, Inc.'s business segments — operating income (loss)?
Indivior Pharmaceuticals, Inc. (INDV) reported business segments — operating income (loss) of $137M in Q1 2026.
How has Indivior Pharmaceuticals, Inc.'s business segments — operating income (loss) changed year-over-year?
Indivior Pharmaceuticals, Inc.'s business segments — operating income (loss) increased by 107.6% year-over-year, from $66M to $137M.
What is the long-term trend for Indivior Pharmaceuticals, Inc.'s business segments — operating income (loss)?
Over 3 years (2022 to 2025), Indivior Pharmaceuticals, Inc.'s business segments — operating income (loss) has grown at a 47.9% compound annual growth rate (CAGR), from -$81M to $262M.
What does business segments — operating income (loss) mean?
Measures the profitability of the reportable segment by subtracting operating expenses from gross profit. It serves as a key performance indicator for the segment's operational health and management's ability to control costs relative to revenue.

Ask your AI about Indivior Pharmaceuticals, Inc.'s business segments — operating income (loss).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude